| Clinical data | |
|---|---|
| Other names | BIIB124 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| Chemical and physical data | |
| Formula | C24H38N4O3 |
| Molar mass | 430.593 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SAGE-324, also known asBIIB124, is an experimental drug. It is aneurosteroid that works as aGABAA receptor positive allosteric modulator.[1][2][3]
SAGE-324 was being developed byBiogen for the treatment ofessential tremor.[4] Its development was discontinued in 2024 due to lack of efficacy in Phase 2 clinical trials.[5]